Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROAR: Reversal of opioid-induced respiratory depression with opioid antagonists
2024-518041-16-00Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of naloxone in opioid intoxication, opioid-induced respiratory depression (OIRD) and opioid use disorder (OUD) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Minute ventilation and PK/PD parameters (C50 and t½ke0) for opioids and antagonists. Started Nov 2024; status: completed.
02
Drugs
naloxone
03
Conditions
opioid intoxicationopioid-induced respiratory depression (OIRD)opioid use disorder (OUD)
Beyond the preview
Go deeper on 2024-518041-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518041-16-00.